Late-onset invasive aspergillosis in organ transplant recipients in the current era

Medical Mycology

Volumn 44, Issue 5, 2006, Pages 445-449

  Singh, Nina ^a   Limaye, Ajit ^b   Forrest, Graeme ^c   Safdar, Nasia ^d   Muñoz, Patricia ^e   Pursell, Kenneth ^f   Houston, Sally ^g   Rosso, Fernando ^h   Montoya, Jose ^h   Patton, Pamela ⁱ   Del Busto, Ramon ^j   Aguado, Jose ^k   Wagener, Marilyn ^a   Husain, Shahid ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j HENRY FORD HOSPITAL   (United States)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

Invasive aspergillosis; Transplant recipients

Indexed keywords

AZATHIOPRINE; CASPOFUNGIN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; B LYMPHOCYTE; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFILTRATE; LYMPHOCYTE DEPLETION; MALE; OBSERVATIONAL STUDY; ORGAN TRANSPLANTATION; PREDICTION; PROSPECTIVE STUDY; SURGICAL MORTALITY; T LYMPHOCYTE; TREATMENT PLANNING;

ADULT; AGE OF ONSET; AGED; ANTIBODIES; ANTIFUNGAL AGENTS; ASPERGILLOSIS; B-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; SPAIN; T-LYMPHOCYTES; TACROLIMUS; TREATMENT OUTCOME; UNITED STATES;

ASPERGILLUS;

EID: 33746814901     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780600684494     Document Type: Article

References (21)

1. Gavalda J, Len O, San Juan R,. for RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis 2005; 41: 52-59.
2. Montoya, JG and Chaparro, SV and Celis, D and (2003) Invasive aspergillosis in the setting of cardiac transplantation Clin Infect Dis, 37, pp. S281-S292.
3. Munoz, P and Rodriguez, C and Bouza, E and (2004) Risk factors of invasive aspergillosis after heart transplantation: Protective role of oral itraconazole prophylaxis Am J Transplan, 4, pp. 636-643.
4. Paterson, DL and Singh, N. (1999) Invasive aspergillosis in transplant recipients Medicine, 78, pp. 123-138.
5. Singh, N and Avery, RK and Munoz, P and (2003) Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients Clin Infect Dis, 36, pp. 46-52.
6. Singh N, Limaye A, Safdar N,. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients (abstract M717). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16-19 December 2005.
7. Ascioglu, S and Rex, JH and Bennett, JE and (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus Clin Infect Dis, 34, pp. 7-14.
8. Husain, S and Munoz, P and Forrest, G and (2005) Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: Clinical characteristics and impact of antifungal agent therapy on outcome Clin Infect Dis, 40, pp. 89-99.
9. Husain, S and Alexander, B and Munoz, P and (2003) Opportunistic mycelial fungi in organ transplant recipients; emerging importance of non-Aspergillus mycelial infections Clin Infect Dis, 37, pp. 221-229.
10. Halloran, PF. (2004) Immunosuppressive drugs for kidney transplantation N Engl J Med, 351, pp. 2715-2729.
11. Cruz, MC and Goldstein, AL and Blankenship, JR and (2002) Calcineurin is essential for survival during membrane stress in Candida albicans EMBO, 21, pp. 546-559.
12. Odom, A and Del Poeta, M and Perfect, J and Heitman, J. (1997) The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein Antimicrob Ag Chemother, 41, pp. 156-161.
13. High, KP and Washburn, RG. (1997) Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin) J Infect Dis, 175, pp. 222-225.
14. Steinbach, WJ and Singh, N and Miller, JL and (2004) In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and non-transplant patients Antimicrob Ag Chemother, 48, pp. 4922-4925.
15. Panackal, AA and Dahlman, A and Keil, KT and (2003) Outbreak of invasive aspergillosis among renal transplant recipients Transplantation, 15, pp. 1050-1053.
16. Mendez R, Gonwa T, Yang HC,. for the Prograf Study Group. A prospective, randomized trial of tacrolimus in combination with sirolimus of mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005; 80: 303-309.
17. Peddi, VR and Jensik, S and Pescovitz, M and (2005) An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency Clin Transplant, 19, pp. 130-136.
18. Diekmann, F and Budde, K and Oppenheimer, F and (2004) Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction Am J Transplant, 4, pp. 1869-1875.
19. Schooley, RT and Hirsch, MS and Colvin, RB and (1983) Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation N Engl J Med, 308, pp. 307-313.
20. Rook, AH. (1988) Interactions of cytomegalovirus with the human immune system Rev Infect Dis, 10, pp. S460-S467.
21. Laursen, A and Mogensen, S and Andersen, H and Andersen, P and Ellermann-Erksen, S. (2001) The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii Clin Exp Immunol, 123, pp. 239-246.